Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • My alerts
  • Log in
  • Log out
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

α9 Integrin and Its Ligands Constitute Critical Joint Microenvironments for Development of Autoimmune Arthritis

Masashi Kanayama, Daisuke Kurotaki, Junko Morimoto, Tsuyoshi Asano, Yutaka Matsui, Yosuke Nakayama, Yoshinari Saito, Koyu Ito, Chiemi Kimura, Norimasa Iwasaki, Koji Suzuki, Tanenobu Harada, Hong Mei Li, Jun Uehara, Tadaaki Miyazaki, Akio Minami, Shigeyuki Kon and Toshimitsu Uede
J Immunol June 15, 2009, 182 (12) 8015-8025; DOI: https://doi.org/10.4049/jimmunol.0900725
Masashi Kanayama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daisuke Kurotaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junko Morimoto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tsuyoshi Asano
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yutaka Matsui
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yosuke Nakayama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshinari Saito
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koyu Ito
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chiemi Kimura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norimasa Iwasaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koji Suzuki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tanenobu Harada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong Mei Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Uehara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tadaaki Miyazaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akio Minami
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shigeyuki Kon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshimitsu Uede
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF + SI
  • PDF
Loading

Abstract

Osteopontin is critically involved in rheumatoid arthritis; however, the molecular cross-talk between osteopontin and joint cell components that leads to the inflammatory joint destruction is largely unknown. We found that not only osteopontin but also tenascin-C and their common receptor, α9 integrin, are expressed at arthritic joints. The local production of osteopontin and tenascin-C is mainly due to synovial fibroblasts and, to a lesser extent, synovial macrophages. Synovial fibroblasts and macrophages express α9 integrin, and autocrine and paracrine interactions of α9 integrin on synovial fibroblasts and macrophages and its ligands contribute differently to the production of proinflammatory cytokines and chemokines. α9 integrin is also involved in the recruitment and accumulation of inflammatory cells. Inhibition of α9 integrin function with an anti-α9 integrin Ab significantly reduces the production of arthrogenic cytokines and chemokines and ameliorates ongoing arthritis. Thus, we identified α9 integrin as a critical intrinsic regulator that controls the development of autoimmune arthritis.

Rheumatoid arthritis (RA)4 is a complex, multisystem disease. The role of inflammatory cells in the pathogenesis of RA has been well established. However, the significance of resident cells within the synovial membrane has only recently begun to be fully appreciated (1, 2). One important characteristic of synovial cells is their attachment to the cartilage extracellular matrix (ECM) proteins, facilitating their invasion into cartilage and bone tissues to cause joint destruction. The interaction of those synovial cells with ECM proteins is mediated by adhesion molecules such as integrins. Integrins mediate not only cell attachment but also intracellular signaling pathways (3, 4). Osteopontin (OPN) has been characterized as an ECM protein. However, OPN is now recognized as one of the matricellular proteins that, unlike classical ECM proteins, are soluble proteins and exert proinflammatory responses (5, 6, 7). Indeed, overexpression of OPN has been associated with various inflammatory disorders in human and mice including Crohn’s disease, multiple sclerosis, RA, and autoimmune arthritis (8, 9, 10, 11, 12, 13, 14, 15, 16). Another matricellular protein, tenascin-C (TN-C), is also significantly up-regulated at the pathologic foci of RA (17). The lack of OPN and TN-C abrogates the development of Th1 type immunity-mediated diseases, including autoimmune arthritis and hepatitis in mice (18, 19, 20). OPN and TN-C each bind to multiple receptors but share a common receptor, the α9β1 integrin (21). It has been shown that the α9 integrin is involved in the transendothelial migration of neutrophils into inflammatory foci in human and in the generation of osteoclasts in both human and mouse (22, 23). However, it is unclear whether the interaction between the α9 integrin and its ligands, OPN and TN-C, within the joint tissue microenvironment plays any mechanistic role for the development of inflammatory autoimmune arthritis. Collagen Ab-induced arthritis (CAIA) has recently been used extensively to study the inflammatory phase of arthritis in which the critical involvement of not only IL-1 but also OPN has been documented (18, 24, 25). Therefore, we examined how OPN and TN-C and their receptor, the α9 integrin, can be integrated into the pathogenesis of arthritis.

In this study we provide evidence that the α9 integrin and its ligands are critical intrinsic regulators that control the development of autoimmune arthritis. In the arthritic microenvironment, both synovial fibroblasts and macrophages express the α9 integrin. There are more fibroblasts than macrophages in arthritic joints, and fibroblasts are the major sources of locally produced OPN and TN-C. Importantly, the α9 integrin differentially regulates the production of cytokines and chemokines by each cell type. α9-mediated production of these cytokines and chemokines then presumably contributes to the recruitment of inflammatory cells into the synovium, osteoclast activation, synovial hyperplasia, pannus formation and, cartilage and bone destruction. Importantly, inhibition of the α9 integrin function with an inhibitory anti-α9 integrin Ab significantly reduces the production of arthrogenic cytokines and chemokines and ameliorates ongoing arthritis. These results suggest that the α9 integrin serves as a novel therapeutic target for the treatment of autoimmune disorders, including RA.

Materials and Methods

Antibody

Anti-human α4 and α9 integrin Abs were purchased from Chemicon. PE- or FITC-Mac-1, FITC-Gr-1, FITC-VCAM-1, PE-TLR-4, biotinylated anti-class II, and streptavidin-allophycocyanin were purchased from BD Pharmingen. Anti-murine α4 integrin Ab and FITC-F4/80 from eBioscience and Serotec, respectively. Anti-vimentin and anti-smooth muscle actin (SMA) Abs were from Sigma-Aldrich. PE-anti-human Mac-1 was purchased from Boehringer Mannheim. An Ab (D7-FIB) that reacts to human fibroblasts (26) was obtained from Serotec. Anti-human OPN, anti-mouse OPN, and anti-human TN-C Abs used for immunohistology were purchased from Immuno-Biological Laboratories.

Transfectants

A murine α9 integrin was cloned into the pcDNA3.1 vector from cDNA derived from B16-BL6 cells using a pair of primers, α9 integrin-5′ (5′-GCTAAGCTTCTGGGGATGGGCGGCCCGGCT-3′) and α9 integrin-3′ (5′-CCATCTAGATCACTGGTTTTTCTGGACCCA-3′). A murine α4 integrin was cloned into the pcDNA3.1 vector from cDNA derived from B16-BL6 cells using the primer pair α4 integrin-5′ (5′-CGTGGATCCGAGCGCATGGCTGCGGAAGCGAGGTGC-3′) and α4 integrin-3′ (5′-CAGCTCGAGTCAGTCATCATTGCTTTTGCTGTTGAC-3′). These constructs were transfected to Chinese hamster ovary (CHO)-K1 cells or NIH3T3 cells with Lipofectamine 2000. Stable transfectants were selected by G418 (Sigma-Aldrich). CHO-K1 cells or NIH3T3 cells, transfected with murine α9 (or α4) integrin were referred to as α9/CHO or α9/NIH (α4/CHO or α4/NIH), respectively.

Production of anti-murine α9 integrin Ab

Armenian hamsters were immunized with α9/CHO cells and splenocytes were fused with X63-Ag8-653 mouse myeloma cells according to the standard procedure. Hybridoma cells, secreting IgG Abs specifically bound to α9/NIH cells but not to α4/NIH cells, were recovered.

Real time-PCR analysis

Total RNA was isolated from ankle joints, synovial fibroblasts, or macrophages from ankle joints using TRIzol (Invitrogen) and first-strand cDNA was generated with a first-strand cDNA synthesis kit (GE Healthcare Biosciences). Real-time quantitative PCR was performed using the LightCycler FastStart DNA Master SYBR Green I system (Roche Diagnostics). Some of the specific primers using in this study were shown in supplemental Table I.5 The expression level of mRNA was calculated by the calibration curve method using LightCycler software version 3. Data were standardized by G3PDH.

Induction and clinical assessment of arthritis in mice

Arthritis in BALB/c mice was induced by using an arthritogenic mAb cocktail kit (Immuno-Biological Laboratories) and treatment protocol was depicted in supplemental Fig. 1. The clinical severity of arthritis was graded in each of the four paws on a 0–4 scale. The disease severity was recorded for each limb as follows: 0, normal; 1, focal slight swelling and/or redness in one digit; 2, moderate swelling and erythema of more than two digits; 3, marked swelling and erythema of the limb; and 4, maximal swelling, erythema, deformity and/or ankylosis. The appearance ratio of arthritic limb was calculated by following formula; (the number of arthritic limb/the number of all limbs) × 100.

Histology

Histological assessment of the arthritic joints was conducted using sections stained with Fast Green/safranin-O or H&E. The degrees of synovial proliferation, leukocyte infiltration, and cartilage degeneration were graded as follows: 0, normal; 1, mild proliferation of synovium and minor leukocyte infiltration into synovium or minor erosion of the cartilage; 2, invasion of synovium into the joint space and moderate leukocyte infiltration or mild pannus erosion of the cartilage; and 3, extensive leukocyte infiltration into the joint space, fibrous ankylosis of the joints, and peripheral and subchondral cartilage erosion. In some experiments, content of the cartilage matrix proteoglycan was evaluated by safranin-O staining of joint sections and scored arbitrarily as 0 when normal or as 1–3 according to the degree of depletion (loss of staining). In other experiments, serial frozen sections were made from joints both treated with normal hamster IgG (NHG) or anti-α9 integrin Ab. Sections were fixed with cold acetone and were subjected to tartrate-resistant acid phosphatase (TRAP) staining. The expression of OPN or TN-C in mouse or human synovial tissues was assessed by immunostaining of synovial tissues using specific Abs according to the methods described previously (8, 20).

Measurement of cytokines

Murine IL-6, IL-1α, and TNF-α production in culture supernatant was measured by using ELISA kits as specified by the manufacturers (BD Bioscience or R&D Systems). Murine OPN, thrombin-cleaved form of OPN (OPN N half), and TN-C expression were measured by ELISA (Immuno-Biological Laboratories).

Production of mutated forms of human OPN and TN-C

An amino-terminal half of human OPN (nOPN; I17–R168) in which RGD was mutated to RAA (nOPN/RAA) (27) was cloned into the pGEX6P-1 vector from the full-length OPN cDNA as a template using the following pair of primers: OPN-5′ (5′-TCTGGATCCATACCAGTTAAACAGGCT GAT-3′) and OPN(RAA)-3′ (5′-GCTCTCGAGTTACCTCAGTCCATAAACCACACTAGCAGCTCG-3′. A third fibronectin type III repeat domain of human TN-C (R797–P896) in which RGD was mutated to RAA (TN-Cfn3/RAA) (28) was cloned into pGEX6p-1 from cDNA derived from HT-1080 cells using the following pair of primers; TN-C-5′ (5′-GTTGGATCCAGGGTGACCACCACACGCTTG-3′ and TN-C (RAA)-3′ (5′-TCTCTCGAGTTAGGGAGCATCGAGGCCTGTTGTGAAGGTCTCTTTGGCTGGGTTGCTTGACATGGCAGCTCT-3′). TNCΔ was cloned into the pGEX6p-1 vector from TN-Cfn3/RAA construct as a template using the following pair of primers: TNCΔ-5′ (5′-GCCTTGATCACCTGGTTCAAGCCCACCTACGGCATCAAAGACGTGCC-3′) and TNCΔ-5′ (5′-GGCACGTCTTTGATGCCGTAGGTGGGCTTGAACCAGGTGATCAAGGC-3′). pGEX plasmid were transformed to JM109-competent cells and the GST fusion proteins were purified with glutathione-Sepharose 4B beads. The proteins were then cut off from GST with PreScission protease (GE Healthcare).

Adhesion assays

Cell binding assays were performed as described previously (29). Briefly, the 96-well plates were precoated with BSA or mutated forms of human nOPN/RAA or TN-Cfn3/RAA (1.25 μg/ml) or, in some experiments, with the synthetic peptides SVVYGLR, AEIDGIEL, or GRGDS (10 μg/ml), followed by blocking with 1% BSA in PBS for 1 h at room temperature. After washing with PBS, synovial fibroblasts or α9/NIH cells (1 × 104) were added to the wells and incubated at 37°C for 1 h. The adherent cells were fixed and stained with 0.5% crystal violet in 20% methanol for 30 min and then lysed with 20% acetic acid. The resultant supernatants from each well were analyzed by an immunoreader and absorbance at 590 nm was measured to determine the relative number of cells adhered to wells.

Cytokine, chemokine, and OPN and TN-C production assays

Murine synovial fibroblasts and macrophages (3 × 103) were cultured on plates coated with mutated forms of human nOPN/RAA, TN-Cfn3/RAA, or TN-CΔ (2.5–10 μg/ml) for 48 h in FCS-free medium. Cells were lysed with TRIzol reagent (Invitrogen) and subjected to the analysis of cytokine gene expression using real-time PCR. Culture supernatants were subjected to the measurement of cytokine and OPN or TN-C production by ELISA.

Isolation and fractionation of synovial tissues

In Fig. 1⇓D, first the ankle joint portion of a leg was surgically cut and separated from other area and then the dermal, subcutaneous, tendinous, and muscle tissues were surgically taken off from joints under a dissecting microscope. The remaining soft tissues were surgically separated from bone tissues and were used as synovial tissues. In Figs. 2⇓C and 5–7, these soft tissues were treated with 0.1% type II collagenase (Worthington Biochemical) at 37°C by vigorous stirring. After washing, synovial cells were cultured in 10% FCS containing medium at 37°C overnight. Attached cells were regarded as “adherent cells” and unattached cells were regarded as “nonadherent cells” and were used in Fig. 5 for expression analysis of cell surface Ag. For functional analysis, synovial cells were fractionated into TLR-4+ or TLR-4− fractions by using MACS (Miltenyi Biotec). The TLR-4+ fraction contained ∼90% Mac-1+Gr-1− cells and was thus used as a macrophage in Fig. 7 and supplemental Fig. 4. The TLR-4− fraction was cultured overnight and nonadherent cells were discarded. Adherent cells were enriched for Mac-1−Gr-1− cells (∼90%) and used as fibroblasts in Fig. 6 and supplemental Fig. 4. Human synovial specimens were obtained through synovectomy from patients who fulfilled the American College of Rheumatology criteria for RA. Informed consent was obtained from all study subjects before sample collection. The study protocol was approved by the institutional review board at the Hokkaido University Graduate School of Medicine. Human synovial cell suspension was made by the method described above for mouse synovial cells.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

Augmented expression of α9 integrin and its ligands, OPN and TN-C, in arthritic joints. A, Kinetic analysis of gene expression of α9 integrin and its ligands. Total RNA extracted from the ankle joint synovial tissue of individual mice with arthritis was subjected to quantitative real-time PCR. Expression levels are normalized to G3PDH. Error bars represent mean ± SEM (n > 4 per group). B and C, Immunohistochemical detection of OPN or TN-C in arthritic joints of mouse (B) and patients (C). Representative histology was shown. Magnified views of boxed areas in upper panels are shown in lower panels; n = 3 per group. Cont, Control. D, OPN, TN-C, and a thrombin-cleaved form of OPN (OPN N half) in synovial tissue derived from normal or arthritic joints were measured by ELISA. Error bars represent mean ± SEM (n = 4 for normal and day 6 samples; n = 3 for day 3 sample). Values are expressed as nanograms or femtomoles per milligram of synovial tissue. ∗, p < 0.05; ∗∗, p < 0.01.

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

Inhibition of arthritis by prophylactic administration of anti-α9 integrin Ab. A, Disease score of arthritic mice treated with NHG, 18R18D, or 55A2C at the indicated time points. Arrows indicate the date of Ab injection. Error bars denote mean ± SEM (n > 8 per group). B, The appearance ratio of an arthritic limb in mice treated with NHG or 55A2C. C, Cell components of normal or arthritic joints at days 3 and 6, treated with either NHG or 55A2C, were analyzed by FACS. The Mac-1+Gr-1+ fraction, the Mac-1+Gr-1− fraction, and the Mac-1−Gr-1− fraction were defined as neutrophils, macrophages, and fibroblasts, respectively. Error bars denote mean ± SEM (n = 3 per group). D, Representative histology of normal joints and arthritic joints at day 3 from mice treated with NHG or 55A2C. Sections were stained with H&E. Magnified views of boxed area in left and middle panels were shown in the middle and right panels, respectively; n = 3 per group. The results of histological analysis in terms of inflammatory cell infiltration are summarized in the right panel with statistical evaluation. E, Analysis of gene expression of chemokines. Total RNA extracted from the ankle joints of normal or arthritic mice at day1 treated with either NHG or 55A2C were subjected to quantitative real-time PCR. Expression levels are normalized to G3PDH. Error bars represent mean ± SEM (n > 3 per group). ∗, p < 0.05; ∗∗, p < 0.01.

Measurement of protein level in synovial tissues

Synovial tissues obtained from normal or arthritic joints were pulverized by a homogenizer (Polytoron PT1600E; Kinematica) in 12.75 μl/mg PBS containing a protease inhibitor cocktail (Roche Diagnostics). The suspension of synovial tissues mixed with 1.5 μl/mg tissue 10% Triton and 0.75 μl/mg 10% Nonidet P-40 were vortexed and incubated on ice for 30 min. Then, the suspension were centrifuged at 15,000 rpm for 30 min and supernatant was collected. OPN and TN-C concentrations were measured by ELISA.

Flow cytometric analysis

Murine synovial cells were stained with PE-Mac-1 and FITC-Gr-1. After washing, cells were further stained with biotinylated anti-mouse α4 or α9, followed by streptavidin-allophycocyanin. In other experiments, cells were stained with FITC-Mac-1 and PE-TLR-4, FITC-Mac-1 and PE-VCAM-1, or PE-Mac-1 and FITC-F4/80. In some experiments, cells were stained with FITC-Mac-1 and biotinylated anti-mouse class II, followed by streptavidin-allophycocyanin. Human synovial cells were stained with FITC-D7-FIB and PE-Mac-1. After washing, cells were further stained with biotinylated anti-human α9 integrin, followed by streptavidin-allophycocyanin as described above. All analyses were performed on a FACSCalibur flow cytometer (BD Biosciences) with FlowJo software (Tree Star).

Statistical analysis

Statistical evaluation was performed based on the Student’s t test to compare the differences between groups. For calculation of the appearance ratio of arthritic joint, χ2 statistics were derived using the CHIDIST function of Microsoft Excel. Single (∗) and double asterisks (∗∗) indicate that values are significantly different between control and experimental group, with values of p < 0.05 or p < 0.01, respectively.

Results

Expression of α9 integrin and its ligands in pathological foci of inflammatory arthritis

The murine model of RA was induced by i.v. administration of a mixture of four anti-type II collagen mAbs followed by i.p. administration of LPS. We surgically dissected arthritic joints and carefully obtained synovial tissues. Gene expression of both the α9 integrin and its ligands, OPN and TN-C, was significantly up-regulated in synovial tissues of arthritis joints after LPS injection (Fig. 1⇑A). α4 integrin gene expression was also induced. OPN and/or TN-C proteins were clearly expressed by hyperplastic synovial tissues obtained not only from arthritic mice but also from RA patients (Fig. 1⇑, B and C, respectively). To confirm that synovial tissues produce OPN and TN-C, synovial tissues were obtained at the indicated time points and OPN and TN-C contents were examined by ELISA. Compared to normal synovial tissues, synovial tissues obtained on days 3 and 6 produced significantly more OPN and TN-C. OPN production was ∼2- to 3-fold higher than production of TN-C. Of note, the thrombin-cleaved form of OPN (designated as OPN N half), which is capable of interacting with α9 integrin (27), was increased in arthritic joints at days 3 and 6 but was not found in normal joints (Fig. 1⇑D).

A detailed functional study of the α9 integrin in autoimmune arthritis has been hampered by the early postnatal mortality of the α9 knockout (30) and the lack of specific mAbs recognizing the murine α9 integrin. Thus, we generated both inhibitory and noninhibitory mAbs the specifically react to the murine α9 integrin (supplemental Fig. 2). Anti-α9 integrin Abs could react with murine fibroblasts transfected with the α9 integrin (α9/NIH) but not with those transfected with the α4 integrin (α4/NIH). In addition, those Abs could detect endogenous α9 integrins expressed by the B16-BL6 murine malignant melanoma cells. Importantly, one of the anti-α9 integrin Abs (55A2C) could inhibit the binding of α9/NIH cells to the synthetic peptides SVVYGLR and AEIDGIEL but not to the GRGDS peptide. It has been shown that SVVYGLR or AEIDGIEL are specific ligands for the α9 integrin and correspond to the internal sequences of OPN and TN-C, respectively (27, 28). The binding of α9/NIH cells to the GRGDS peptide is mediated by RGD-recognizing integrins and, thus, the anti-α9 integrin Ab is unable to inhibit it. Thus, a specific anti-α9 integrin blocking Ab, 55A2C, allows us to evaluate the role of α9 integrin in the pathogenesis of inflammatory arthritis.

Attenuation of arthritis by prophylactic or therapeutic administration of anti-α9 integrin Ab

Arthritis was induced by the injection of a cocktail of Abs against type II collagen on day −3 and was followed by LPS injection on day 0. Mice were treated twice with anti-α9 integrin Ab before the onset of arthritis at days −4 and 0 (supplemental Fig. 1). The joint swelling became evident at day 2 and reached its peak at day 6. The severity of arthritis was significantly reduced by an inhibitory anti-α9 integrin Ab (55A2C), but not by a noninhibitory Ab (18R18D) (Fig. 2⇑A). In addition, the appearance ratio of an arthritic limb was also reduced by 55A2C treatment (Fig. 2⇑B). We then analyzed the cellular composition of arthritic joints at different time points after arthritis induction. Under normal conditions there were four times as many fibroblasts as macrophages, and neutrophils were not detected. Fibroblasts increased ∼2- and then 3-fold at days 3 and 6, respectively, as compared with a normal joint (Fig. 2⇑C). Nevertheless, macrophages and neutrophils increased at days 3 and 6. However, fibroblasts remained the dominant cell type in arthritic joints up to day 6, when arthritis reached its peak. Of note, the numbers of all cells were significantly reduced by 55A2C treatment (Fig. 2⇑C). Consistent with the cell counts, histological analysis performed at the early phase of arthritis on day 3 after LPS injection demonstrated the presence of acute inflammation as evidenced by marked interstitial edema and moderate leukocyte accumulation without evident cartilage and bone degeneration. Acute inflammation was significantly attenuated by 55A2C treatment (Fig. 2⇑D). Expressions of CCL2 and CCL4, chemotactic factors involved in leukocyte recruitment, were significantly augmented at day 1, when arthritis was not yet clinically evident and was significantly reduced by 55A2C treatment (Fig. 2⇑E).

In the late phase of arthritic joints at day 14 there was marked synovial hyperplasia and inflammatory cell infiltration consisting of mainly macrophages (marked by closed arrowheads; Fig. 3⇓A) and neutrophils (marked by arrows; Fig. 3⇓A). We also noticed the pannus formation and the appearance of irregularity on bone surfaces (marked by arrows; Fig. 3⇓B), indicating the presence of prominent bone absorption. The appearance of those pathological changes was significantly inhibited by 55A2C (Fig. 3⇓, A–C). Joint histology on day 14 clearly demonstrated the presence of erosion and cartilage degeneration (marked by closed arrowheads; Fig. 3⇓D) and the loss of safranin-O staining (marked by open arrowheads; Fig. 3⇓D) of a joint section, which indicate the loss of proteoglycan in arthritic joints. Joint degeneration was clearly attenuated by 55A2C (Fig. 3⇓D). To further evaluate bone absorption, we immunohistochemically detected TRAP-positive multinuclear cells, presumably activated osteoclasts. There were numerous TRAP-positive multinucleated cells along the periosteal surface of the metatarsal bones in arthritic joints (Fig. 3⇓E). However, those cells were hardly detected in Ab-treated mice, which is consistent with a role for the α9 integrin in the differentiation and activation of osteoclasts as previously suggested (23, 24).

FIGURE 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3.

α9 integrin is critically involved in synovial inflammation, hyperplasia, and joint destruction. A and B, Representative histology of arthritic joints at day 14 from mice treated with NHG or 55A2C. Sections were stained with H&E. Magnified views of boxed areas in the upper panels were shown in the lower panels. C, Results of the histological analysis are summarized with statistical evaluation. Error bars represent mean ± SEM, n = 3 per group; ∗, p < 0.05; ∗∗, p < 0.01. D, Representative histology of normal joints and arthritic joints at day 14 from mice treated with NHG or 55A2C. Sections were stained with H&E or safranin-O. E, Representative immunohistology (day 6) of TRAP-positive, multinucleated, osteoclast-like cells in mice treated with either NHG or 55A2C. Magnified views of boxed areas in left panels were shown in right panels. Arrows indicate TRAP-positive osteoclasts; n = 3 per group.

To mimic a therapeutic intervention as might be relevant to human RA patients, we injected 55A2C after the clinical symptom became evident on day 3, resulting in a marked reduction of the clinical score of arthritis (Fig. 4⇓A) that was consistent with the improvement of joint histology such as synovial hyperplasia, inflammatory cell infiltration, pannus formation, and bone and cartilage destruction at day 14 (Fig. 4⇓, B and C). The results indicated that the α9 integrin is also involved in late phase of arthritis where sustained leukocyte infiltration, synovial hyperplasia, and cartilage and bone destruction dominate local pathology.

FIGURE 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4.

Amelioration of ongoing arthritis by therapeutic administration of the anti-α9 integrin Ab. A, Disease scores of arthritic mice treated with NHG or 55A2C at the indicated time points. An arrow indicates the date of Ab injection. Error bars represent mean ± SEM (n = 8 per group). B, Representative histology of arthritic joints from mice treated with NHG or 55A2C at day 14. Sections were stained with H&E. Magnified view of boxed area in the left and middle panels were shown in the middle and right panels, respectively; n = 3 per group. C, The results of histological analysis in terms of synovial hyperplasia, inflammatory cell infiltration, pannus formation, and bone and cartilage degeneration are summarized with statistical evaluation. D–F, Analysis of gene expression of α9 integrin and its ligands OPN and TN-C (D), cytokines (E), and chemokines (F). Total RNA extracted from the ankle joints of individual mice used in A at day 9 and were subjected to quantitative real-time PCR. Expression levels are normalized to G3PDH. Error bars represent mean ± SEM (n > 3 per group). ∗, p < 0.05; ∗∗, p < 0.01.

In vivo interaction between α9 integrin and its ligand induces production of arthrogenic cytokines and chemokines

To elucidate molecular mechanisms that might account for the attenuation of autoimmune arthritis by therapeutic administration of an anti-α9 integrin Ab, we examined the expression of α9 integrin and its ligands in arthritic joints at day 9. The expression of the α9 integrin and its ligands was not significantly altered by 55A2C treatment, whereas the expression of the α4 integrin was significantly reduced (Fig. 4⇑D). Therefore, it is likely that 55A2C interferes with the ligand-receptor interaction without affecting expression of the α9 integrin and its ligands. In arthritic joints, the expressions of various cytokines that are involved in the pathogenesis of inflammatory arthritis are up-regulated at day 9 (Fig. 4⇑E). Importantly, the augmented expressions of IL-1β, IL-6, and TGF-β in arthritic joints were significantly down-regulated by 55A2C treatment. In contrast, the expressions of IFN-γ and TNF-α were not inhibited by 55A2C treatment (Fig. 4⇑E). We also evaluated the expressions of various chemokines that are chemotactic for monocytes, macrophages, and neutrophils at day 9 (Fig. 4⇑F). The expressions of CCL2 and CXCL2 were not augmented in arthritic joints at day 9 (note that CCL2 was significantly expressed at day 1; see Fig. 2⇑E). However, the expression of CXCL5, which shares the common receptor CXCR with CXCL2, was augmented at day 9 and was significantly reduced by 55A2C treatment. The expressions of CCL3 and CCL4, which share the common receptor CCR5, were augmented at day 9 and were significantly reduced by Ab treatment. In addition, the expressions of CXCL12 and CXCL14 were also augmented in arthritic joints and were again reduced by Ab treatment. Taken together, our results indicated that an anti-α9 integrin Ab inhibits the production of cytokines and chemokines in arthritic joints, leading to the inhibition of macrophage and neutrophil recruitment into joints.

The expression of α9 integrin by synovial fibroblasts and macrophages in both human and mouse

We then examined which cell components within arthritic joints express the α9 integrin. Synovial tissues obtained at day 6 were fractionated into adherent and nonadherent fractions. The majority of adherent cells were Mac-1−Gr-1− cells (Fig. 5⇓A) and were positive for vimentin and negative for anti-SMA and exhibited morphological features of synovial fibroblasts (Fig. 5⇓B). Those synovial fibroblasts express the α9 but not the α4 integrin (see “R3” in Fig. 5⇓A). Approximately 20% of adherent cells are Mac-1+Gr-1− macrophages and express both α9 and α4 integrins (see “R1” in Fig. 5⇓A). There is a small fraction of Mac-1+Gr-1+ neutrophils. Unexpectedly, we found that synovial neutrophils express the α4 integrin but do not express the α9 integrin (see “R2” in Fig. 5⇓A). The nonadherent cell population also consisted of Mac-1+Gr-1− macrophages, Mac-1−Gr-1− fibroblasts, and Mac-1+Gr-1+ neutrophils, which represent a major population (Fig. 5⇓A). The integrin expression profiles are indistinguishable from those of the corresponding subsets in the adherent cell population (data not shown). We next fractionated the adherent cell population into Mac-1+ (see “R1” in Fig. 5⇓C) and Mac-1− (see “R2” in Fig. 5⇓C) populations. Mac-1+ adherent cells expressed F4/80, and thus those cells were enriched for macrophages. Synovial macrophages express class II and TLR-4 but little if any VCAM-1 (Fig. 5⇓C). In contrast, the Mac-1− cell population was negative for F4/80 and thus those cells were enriched for fibroblasts. Synovial fibroblasts clearly expressed VCAM-1 but little if any TLR-4 (Fig. 5⇓C). We also examined whether human arthritic synovial cells express the α9 integrin. Synovial cells obtained from RA patients were fractionated into Mac-1+D7-FIB+ synovial macrophages (se “R1” in Fig. 5⇓D) and Mac-1−D7-FIB+ synovial fibroblasts (see “R3” in Fig. 5⇓D). Both human synovial macrophages and fibroblasts express significant surface levels of the α9 integrin (Fig. 5⇓D). It should be noted that both α9 and α4 integrins specifically bind to VCAM-1 (21, 31). Thus, our data indicate that VCAM-1 expressed by synovial fibroblasts may provide an anchor for cell attachment and the recruitment of inflammatory cells that express its counter receptor, the α4 integrin (neutrophils and macrophages) and/or the α9 integrin (macrophages).

FIGURE 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 5.

Expression of α9 integrin by synovial cells obtained from arthritic joints. A, Synovial tissues obtained from joints of arthritic mice were fractionated into adherent and nonadherent cell populations. Synovial fibroblasts (R3), macrophages (R1), and neutrophils (R2) were stained for cell surface expression of α9 and α4 integrins. B, Murine synovial fibroblasts obtained from arthritic joints were stained for anti-SMA (α-SMA) and vimentin. C, The adherent cell population in A was further fractionated into Mac-1+ (R1) and Mac-1− (R2) fractions and were stained for cell surface expression of TLR-4, VCAM-1, class II, and F4/80. FSC, forward scatter. For A–C, cells were obtained from synovial tissues from arthritic joints of 3–5 mice at day 6. Data are representative of three experiments. D, Cell suspensions were prepared from inflamed synovial tissues of RA patients. Cells were divided into two populations, synovial fibroblasts (R3) and synovial macrophages (R1), and were stained for cell surface expression of α9 integrin. Data are representative of three independent experiments using synovial tissues derived from three independent RA patients.

Synovial fibroblasts and macrophages differentially contribute to the pathogenesis of arthritis

Synovial fibroblasts are the predominant cell components within arthritic joints (Fig. 2⇑C). Therefore, we first attempted to clarify the role of synovial fibroblasts in the pathogenesis of inflammatory arthritis. Murine synovial fibroblasts obtained from arthritic joints bound to recombinant OPN (nOPN/RAA) and TN-C (TN-Cfn3/RAA) proteins, which are ligands for α9 integrins (Fig. 6⇓A). The recombinant OPN and TN-C fragments used in these experiments were genetically modified so that the RGD sequence, which can be recognized by an RGD-recognizing integrin, was replaced by RAA, thus allowing the study of α9 integrin-dependent cell adhesion without the confounding effects of RGD-binding integrins (27, 28). In addition, the binding was specifically inhibited by an inhibitory anti-α9 integrin Ab. These data indicate that the α9 integrin can mediate the cell adhesion of synovial fibroblasts to OPN and TN-C, enabling the strong interaction of fibroblasts with a joint ECM, which culminates in the destruction of cartilage and bone. We also found that the detachment of fibroblasts, both NIH3T3 transfected with the murine α9 integrin (α9/NIH) and the parent NIH3T3, resulted in the significant cell death in vitro (detachment induced-cell death or anoikis) and the anoikis was significantly inhibited in α9/NIH but not in α9-negative fibroblasts (NIH3T3) by the synthetic SVVYGLR peptide, which corresponds to the α9 integrin recognition sequence within OPN (27) (supplemental Fig. 3). The rescue from anoikis of α9/NIH fibroblasts by the SVVYGLR peptide was reversed by the addition of an anti-α9 integrin Ab, indicating that the rescue from anoikis is α9 integrin dependent. Of note, the thrombin-cleaved form of OPN, which exposes the SVVYGLR sequence, is elevated in arthritic joints (Fig. 1⇑D) and in RA patients, and detached fibroblasts are frequently seen in the synovial fluid of RA patients (2, 32, 33). Thus, our data favor the hypothesis that synovial hyperplasia is enhanced by the impairment of synovial fibroblast cell death through the interaction between the α9 integrin and its ligands.

FIGURE 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 6.

Activation of synovial fibroblasts through interaction of α9 integrin with its ligands. Synovial fibroblasts (3 × 103 to 1 × 104) obtained from the joints of arthritic mice were plated on plates coated with BSA, OPN (nOPN/RAA), or TN-C (TN-Cfn3/RAA) (1.25–10 μg/ml) in the presence or absence of 55A2C or NHG (10 μg/ml). A, After 1 h of culture, bound cells were counted. Error bars represent mean ± SEM (n = 3 per group). B–D, After 48 h of culture, cells were recovered and total RNA extracted was subjected to quantitative real-time PCR analysis. E, After 48 h of culture, supernatants were collected and used for cytokine measurement by ELISA in triplicate wells shown as mean ± SEM. Data are representative of four experiments. ∗, p < 0.05; ∗∗, p < 0.01.

We next asked whether the α9 integrin on synovial fibroblasts contributes to the production of the proinflammatory cytokines and chemokines detected at arthritic joints (Fig. 4⇑, E and F). The stimulation of synovial fibroblasts by the α9 integrin ligands OPN and TN-C resulted in augmented gene expression of proinflammatory cytokines such as IL-1α and IL-6 (Fig. 6⇑B). These cytokines were previously shown to be involved in the activation and recruitment of inflammatory cells (34, 35). However, the expressions of IFN-γ, TNF-α, and IL-1β were not augmented. Among the seven chemokines tested, expressions of CCL2, CXCL5, and CXCL12 were induced by both OPN and TN-C stimulation, while CCL4 expression was slightly induced by TN-C stimulation (Fig. 6⇑C). We also found that matrix metalloproteinase (MMP)-9 expression was induced by OPN and TN-C stimulation of synovial fibroblasts. In contrast, MMP-2 expression was significantly reduced by both OPN and TN-C (Fig. 6⇑D). MMP-9 has been shown to activate various cytokines including TGF-β and IL-1β (36, 37), thus contributing to the pathogenesis of inflammatory arthritis, whereas MMP-2 inactivates chemokines including CCL7 (38), thus down-regulating inflammatory arthritis (39). Production of IL-6 protein was also clearly induced by OPN and TN-C stimulation, and IL-6 production was significantly inhibited by 55A2C treatment (Fig. 6⇑E). Thus, our data demonstrate that interaction between the α9 integrin on synovial fibroblasts and its ligands within joints dramatically modulates fibroblast gene expression in a pattern predicted to contribute to the severity of inflammatory arthritis.

We finally asked whether synovial macrophages also contribute to the production of cytokines and chemokines. Similar to the case of synovial fibroblast stimulation as shown in Fig. 6⇑B, the expressions of IL-6 and IL-1α by synovial macrophages were induced upon stimulation with OPN and TN-C (Fig. 7⇓A). In contrast to case of the synovial fibroblasts, TNF-α and IL-1β expressions by synovial macrophages were also augmented. In addition, TGF-β expression was also increased in synovial macrophages derived from arthritic joints (Fig. 7⇓B). We also found that expressions of CCL2, CCL3, CCL4 CXCL2, and CXCL5, but not those of CXCL12 and CXCL14, were augmented by OPN and TN-C stimulation in synovial macrophages (Fig. 7⇓C). Note that CCL2 and CXCL5 can be produced by both synovial fibroblasts and macrophages. CCL3, CCL4, and CXCL2 were derived from synovial macrophages, but not from fibroblasts. In contrast, CXCL12 was derived from synovial fibroblasts, but not from macrophages (see Fig. 6⇑C). We confirmed that not only gene expressions but also protein expressions of IL-6, IL-1α, and TNF-α were induced by OPN and TN-C stimulation of synovial macrophages (Fig. 7⇓D). The induction of the IL-6 protein by synovial macrophages was mediated by α9 integrin stimulation, because an Ab specific for the α9 integrin could inhibit the production of IL-6 (Fig. 7⇓E) and a mutated form of recombinant TN-C lacking the domain responsible for interaction with the α9 integrin was unable to induce the IL-6 protein (Fig. 7⇓F). Taken together, these data support the notion that synovial fibroblasts and macrophages contribute differently to the production of cytokines and chemokines through the interaction between α9 integrin with its ligands.

FIGURE 7.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 7.

Activation of synovial macrophages through interaction of α9 integrin with its ligands. Synovial macrophages (3 × 103) obtained from joints of arthritic mice were plated on plates coated with BSA, OPN (nOPN/RAA), TN-C (TN-Cfn3/RAA) or TN-CΔ, (which lacks an α9 integrin binding sequence, LAEIDGIEL) (2.5–10 μg/ml) in the presence or absence of 55A2C or NHG (5 μg/ml). A and C, After 48 h of culture, cells were recovered and total RNA was extracted and subjected to quantitative real-time PCR analysis. D–F, After 48 h of culture, supernatants were collected and used for measurement of cytokines by ELISA in triplicate wells shown as mean ± SEM. Data are representative of three experiments. B, Synovial fibroblasts and Mac-1+ macrophages obtained from the joints of normal and arthritic mice at day 9 were subjected to real-time PCR analysis and expression of the TGF-β gene was examined. We obtained similar result in another experiment. ∗, p < 0.05; ∗∗, p < 0.01.

Discussion

Integrins make up a large family of cell surface receptors composed of at least 24 different α/β heterodimers that mediate cell-to-cell and cell-to-matrix interactions and signal transduction (3, 4). Although most members of the integrin family are capable of mediating cell migration (40), the α4 integrin has been shown to be involved in directing leukocyte trafficking to sites of inflammation (41). Importantly, in vivo studies using blocking mAbs and antagonistic peptides have successfully demonstrated that antagonism of the α4 integrin holds promise as an effective therapeutic approach to patients suffering from asthma, RA, multiple sclerosis, and inflammatory bowel diseases (42, 43). The α4 integrin is structurally most closely related to the α9 integrin (44). Interestingly, the α9 and α4 integrins share common ligands such as VCAM-1 and OPN (21, 22, 31, 45). Nevertheless, except for the interaction between VCAM-1 and the α4 integrin, the physiological and pathological importance of the interaction between α9 integrins and their ligands are not fully appreciated.

CAIA has recently been used extensively to study the inflammatory phase of arthritis. Pathogenesis of the CAIA model used in this study has been primarily explained by the activation of complement by an immune complex and the subsequent C5a-mediated neutrophil and macrophage infiltration (46). We demonstrated that OPN and/or TN-C were locally produced (Fig. 1⇑D) and that synovial fibroblasts expressed the α9 integrin (Fig. 5⇑). Thus, we reasoned that the autocrine and paracrine interactions of OPN and/or TN-C and its receptor, α9 integrin, on synovial fibroblasts trigger an early phase of inflammatory events leading to the development of arthritis. Once OPN and/or TN-C is produced locally, autocrine and paracrine interaction of the α9 integrin with its ligands further stimulate fibroblasts to produce more OPN and/or TN-C (supplemental Fig. 4), leading to exacerbation of arthritis.

The α9 integrin plays a critical role in the recruitment of inflammatory cells in many ways. Firstly, the interaction of the α9 integrin on synovial cells with OPN and TN-C expressed at the site of inflamed joints results in the production of chemokines that are responsible for the recruitment and activation of inflammatory cells. Importantly, synovial fibroblasts and macrophages contribute differently for the production of various chemokines such as CCL2, CCL3, CCL4, CXCL2, CXCL5, and CXCL12 (Figs. 6⇑ and 7⇑). Other than chemotactic effect, these chemokines are involved in angiogenesis and osteoclastgenesis, which are crucial for the development of arthritis (47, 48, 49). CXCL12 could stimulate vasculogenesis by the recruitment of endothelial progenitor cells, and CCL2 may also promote neovascularization in inflamed tissues (49). Additionally, CCL2 and CCL3 induce the fusion of preosteoclasts, leading to osteoclast formation and activation (50, 51). CXCL12 has key role in the recruitment and activation of the osteoclast precursor (52). Secondly, the α9 integrin acts as an anchor molecule for cell adhesion. Synovial fibroblasts obtained from arthritis joints express VCAM-1, which serves as a counter-receptor for both α9 and α4 integrins (22, 31). Thus, macrophage infiltration may be due to the interaction between α9 integrin on macrophages and VCAM-1 on synovial cells (Fig. 5⇑C) and endothelial cells (22). In addition, activated synovial fibroblasts interact with inflammatory cells via VCAM-1, and this interaction favors not only recruitment but also the survival of inflammatory cells by impairing apoptosis (2, 53, 54). It should be noted that we found that synovial neutrophils do not express α9 integrins (se “R2” in Fig. 5⇑A). Thus, recruitment of neutrophils into synovial tissues in mice seems to be α9 integrin independent. Thirdly, the interaction of the α9 integrin with its ligand leads to the production of various proinflammatory cytokines that are produced differently by synovial fibroblasts and macrophages. IL-1 and IL-6 were derived from both synovial fibroblasts and macrophages, whereas TNF-α and TGF-β are derived from synovial macrophages (Figs. 6⇑ and 7⇑). These cytokines should accelerate the accumulation of inflammatory cells in the synovium by the induction of chemotactic factors or adhesion molecule expression on leukocytes or endothelial cells (34, 35, 55).

Therapeutic agents that target several cytokines were recently developed and extensively used in the therapy of autoimmune disorders including RA (55). In this study, the blocking of the α9 integrin by an Ab dramatically inhibited ongoing arthritis with the attenuation of not only inflammation but also of bone destruction (Fig. 4⇑). In addition, expressions of proinflammatory molecules including cytokines, chemokines, and protease by synovial cells were induced by an α9 integrin-mediated signal (Figs. 6⇑ and 7⇑). Of note, the expression of TNF-α was not inhibited by an anti-α9 integrin Ab, although clinical and histological scores of arthritis were significantly reduced (Fig. 4⇑). Thus, TNF-α production in inflamed joints was independent of α9 integrin-mediated signaling. It will be important to examine in future studies whether α9 integrin-mediated signaling plays a critical role in the pathogenesis of arthritis in RA patients who are not responding to the anti-TNF-α treatment.

In conclusion, our proposed model for the role of the α9 integrin in the development of arthritis is illustrated in Fig. 8⇓. The autocrine and paracrine interaction of OPN and/or TN-C with its receptor, α9 integrin, on synovial cells results in the production of various proinflammatory molecules. IL-6, IL-1α, CCL2, and CXCL5 could be produced by both synovial fibroblasts and macrophages. IL-1β, TNF-α, CCL3, CCL4, and CXCL2 could be derived from synovial macrophages, but not from fibroblasts. CXCL12 could be derived from synovial fibroblasts, but not from macrophages. Those cytokines and chemokines induce inflammation, promote synovial cell growth, and activate osteoclasts, thus playing a critical role in the development of autoimmune arthritis (34, 56, 57). Importantly, there is cross-talk between synovial fibroblasts and macrophages. MMP-9 expressed by synovial fibroblasts activates TGF-β and IL-1 (36, 37), which are produced by synovial macrophages. Of note, TGF-β stimulates the production of the ECM, including OPN and the induction of integrins by fibroblasts (58, 59). Thus, it is likely that the interaction between α9 integrin and its ligands activates synovial component cells and controls the inflammation and subsequent bone destruction via the expression of various inflammatory molecules.

FIGURE 8.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 8.

Schematic illustration of joint tissue microenvironments. The α9 integrin, expressed by synovial fibroblasts and synovial macrophages, and its ligands, OPN and TN-C, provide critical tissue microenvironments for the development of autoimmune arthritis.

Acknowledgments

We express sincere appreciation to Prof. Dean Sheppard at University of California San Francisco for critical reading of the manuscript and for providing valuable suggestions.

Disclosures

The authors have no financial conflict of interest.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • ↵1 This study was supported by Ministry of Education, Culture, Sports, Science, and Technology of Japan Grant 1620914 (to T.U.).

  • ↵2 M.K. and D.K. contributed equally to this study.

  • ↵3 Address correspondence and reprint requests to Dr. Toshimitsu Uede, Division of Molecular Immunology, Institute for Genetic Medicine, Hokkaido University, Kina-15, Nishi-7, Kita-ku, Sapporo 060-0815, Japan. E-mail address: toshi{at}igm.hokudai.ac.jp

  • ↵4 Abbreviations used in this paper: RA, rheumatoid arthritis; CAIA, collagen Ab-induced arthritis; CHO, Chinese hamster ovary; ECM, extracellular matrix; MMP, matrix metalloproteinase; NHG, normal hamster IgG; OPN, osteopontin; nOPN, N-terminal half of OPN; SMA, smooth muscle actin; TN-C, tenascin-C; TRAP, tartrate-resistant acid phosphatase.

  • ↵5 The online version of this article contains supplemental material.

  • Received March 6, 2009.
  • Accepted April 7, 2009.
  • Copyright © 2009 by The American Association of Immunologists, Inc.

References

  1. ↵
    Buckley, C. D.. 2003. Michael Mason prize essay 2003. Why do leucocytes accumulate within chronically inflamed joints?. Rheumatology 42: 1433-1444.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Huber, L. C., O. Distler, I. Tarner, R. E. Gay, S. Gay, T. Pap. 2006. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology 45: 669-675.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Ruoslahti, E.. 1991. Integrins. J. Clin. Invest. 87: 1-5.
    OpenUrlCrossRefPubMed
  4. ↵
    Hynes, R. O.. 1992. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69: 11-25.
    OpenUrlCrossRefPubMed
  5. ↵
    Bornstein, P., E. H. Sage. 2002. Matricellular proteins: extracellular modulators of cell function. Curr. Opin. Cell Biol. 14: 608-616.
    OpenUrlCrossRefPubMed
  6. ↵
    Murphy-Ullrich, J. E.. 2001. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state?. J. Clin. Invest. 107: 785-790.
    OpenUrlCrossRefPubMed
  7. ↵
    O'Regan, A., J. S. Berman. 2000. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int. J. Exp. Pathol. 81: 373-390.
    OpenUrlCrossRefPubMed
  8. ↵
    Ohshima, S., H. Kobayashi, N. Yamaguchi, K. Nishioka, M. Umeshita-Sasai, T. Mima, S. Nomura, S. Kon, M. Inobe, T. Uede, Y. Saeki. 2002. Expression of osteopontin at sites of bone erosion in a murine experimental arthritis model of collagen-induced arthritis: possible involvement of osteopontin in bone destruction in arthritis. Arthritis Rheum. 46: 1094-1101.
    OpenUrlCrossRefPubMed
  9. ↵
    Xu, G., H. Nie, N. Li, W. Zheng, D. Zhang, G. Feng, L. Ni, R. Xu, J. Hong, J. Z. Zhang. 2005. Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J. Clin. Invest. 115: 1060-1067.
    OpenUrlCrossRefPubMed
  10. ↵
    Chabas, D., S. E. Baranzini, D. Mitchell, C. C. Bernard, S. R. Rittling, D. T. Denhardt, R. A. Sobel, C. Lock, M. Karpuj, R. Pedotti, et al 2001. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294: 1731-1735.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Sato, T., T. Nakai, N. Tamura, S. Okamoto, K. Matsuoka, A. Sakuraba, T. Fukushima, T. Uede, T. Hibi. 2005. Osteopontin/Eta-1 upregulated in Crohn’s disease regulates the Th1 immune response. Gut 54: 1254-1262.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Ashkar, S., G. F. Weber, V. Panoutsakopoulou, M. E. Sanchirico, M. Jansson, S. Zawaideh, S. R. Rittling, D. T. Denhardt, M. J. Glimcher, H. Cantor. 2000. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287: 860-864.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Jansson, M., V. Panoutsakopoulou, J. Baker, L. Klein, H. Cantor. 2002. Cutting edge: attenuated experimental autoimmune encephalomyelitis in Eta-1/osteopontin-deficient mice. J. Immunol. 168: 2096-2099.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Hur, E. M., S. Youssef, M. E. Haws, S. Y. Zhang, R. A. Sobel, L. Steinman. 2007. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat. Immunol. 8: 74-83.
    OpenUrlCrossRefPubMed
  15. ↵
    Kitamura, M., K. Iwabuchi, N. Kitaichi, S. Kon, H. Kitamei, K. Namba, K. Yoshida, D. T. Denhardt, S. R. Rittling, S. Ohno, et al 2007. Osteopontin aggravates experimental autoimmune uveoretinitis in mice. J. Immunol. 178: 6567-6572.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Petrow, P. K., K. M. Hummel, J. Schedel, J. K. Franz, C. L. Klein, U. Muller-Ladner, J. Kriegsmann, P. L. Chang, C. W. Prince, R. E. Gay, S. Gay. 2000. Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts. Arthritis Rheum. 43: 1597-1605.
    OpenUrlCrossRefPubMed
  17. ↵
    Salter, D. M.. 1993. Tenascin is increased in cartilage and synovium from arthritic knees. Br. J. Rheumatol. 32: 780-786.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Yumoto, K., M. Ishijima, S. R. Rittling, K. Tsuji, Y. Tsuchiya, S. Kon, A. Nifuji, T. Uede, D. T. Denhardt, M. Noda. 2002. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc. Natl. Acad. Sci. USA 99: 4556-4561.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    El-Karef, A., T. Yoshida, E. C. Gabazza, T. Nishioka, H. Inada, T. Sakakura, K. Imanaka-Yoshida. 2007. Deficiency of tenascin-C attenuates liver fibrosis in immune-mediated chronic hepatitis in mice. J. Pathol. 211: 86-94.
    OpenUrlCrossRefPubMed
  20. ↵
    Diao, H., S. Kon, K. Iwabuchi, C. Kimura, J. Morimoto, D. Ito, T. Segawa, M. Maeda, J. Hamuro, T. Nakayama, et al 2004. Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 21: 539-550.
    OpenUrlCrossRefPubMed
  21. ↵
    Marcinkiewicz, C., Y. Taooka, Y. Yokosaki, J. J. Calvete, M. M. Marcinkiewicz, R. R. Lobb, S. Niewiarowski, D. Sheppard. 2000. Inhibitory effects of MLDG-containing heterodimeric disintegrins reveal distinct structural requirements for interaction of the integrin α9β1 with VCAM-1, tenascin-C, and osteopontin. J. Biol. Chem. 275: 31930-31937.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Taooka, Y., J. Chen, T. Yednock, D. Sheppard. 1999. The integrin α9β1 mediates adhesion to activated endothelial cells and transendothelial neutrophil migration through interaction with vascular cell adhesion molecule-1. J. Cell Biol. 145: 413-420.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Rao, H., G. Lu, H. Kajiya, V. Garcia-Palacios, N. Kurihara, J. Anderson, K. Patrene, D. Sheppard, H. C. Blair, J. J. Windle, et al 2006. α9β1: a novel osteoclast integrin that regulates osteoclast formation and function. J. Bone Miner. Res. 21: 1657-1665.
    OpenUrlCrossRefPubMed
  24. ↵
    Yamamoto, N., F. Sakai, S. Kon, J. Morimoto, C. Kimura, H. Yamazaki, I. Okazaki, N. Seki, T. Fujii, T. Uede. 2003. Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J. Clin. Invest. 112: 181-188.
    OpenUrlCrossRefPubMed
  25. ↵
    Kagari, T., H. Doi, T. Shimozato. 2002. The importance of IL-1β and TNF-α, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J. Immunol. 169: 1459-1466.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Wang, C. T., Y. T. Lin, B. L. Chiang, Y. H. Lin, S. M. Hou. 2006. High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthritis Cartilage 14: 1237-1247.
    OpenUrlCrossRefPubMed
  27. ↵
    Yokosaki, Y., N. Matsuura, T. Sasaki, I. Murakami, H. Schneider, S. Higashiyama, Y. Saitoh, M. Yamakido, Y. Taooka, D. Sheppard. 1999. The integrin α9β1 binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J. Biol. Chem. 274: 36328-36334.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Yokosaki, Y., N. Matsuura, S. Higashiyama, I. Murakami, M. Obara, M. Yamakido, N. Shigeto, J. Chen, D. Sheppard. 1998. Identification of the ligand binding site for the integrin α9β1 in the third fibronectin type III repeat of tenascin-C. J. Biol. Chem. 273: 11423-11428.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Kon, S., M. Ikesue, C. Kimura, M. Aoki, Y. Nakayama, Y. Saito, D. Kurotaki, H. Diao, Y. Matsui, T. Segawa, et al 2008. Syndecan-4 protects against osteopontin-mediated acute hepatic injury by masking functional domains of osteopontin. J. Exp. Med. 205: 25-33.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Huang, X. Z., J. F. Wu, R. Ferrando, J. H. Lee, Y. L. Wang, R. V. Farese, Jr, D. Sheppard. 2000. Fatal bilateral chylothorax in mice lacking the integrin α9β1. Mol. Cell. Biol. 20: 5208-5215.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Morales-Ducret, J., E. Wayner, M. J. Elices, J. M. Alvaro-Gracia, N. J. Zvaifler, G. S. Firestein. 1992. α4/β1 integrin (VLA-4) ligands in arthritis: vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes. J. Immunol. 149: 1424-1431.
    OpenUrlAbstract
  32. ↵
    Neidhart, M., C. A. Seemayer, K. M. Hummel, B. A. Michel, R. E. Gay, S. Gay. 2003. Functional characterization of adherent synovial fluid cells in rheumatoid arthritis: destructive potential in vitro and in vivo. Arthritis Rheum. 48: 1873-1880.
    OpenUrlCrossRefPubMed
  33. ↵
    Ohshima, S., N. Yamaguchi, K. Nishioka, T. Mima, T. Ishii, M. Umeshita-Sasai, H. Kobayashi, M. Shimizu, Y. Katada, S. Wakitani, et al 2002. Enhanced local production of osteopontin in rheumatoid joints. J. Rheumatol. 29: 2061-2067.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Iwakura, Y.. 2002. Roles of IL-1 in the development of rheumatoid arthritis: consideration from mouse models. Cytokine Growth Factor Rev. 13: 341-355.
    OpenUrlCrossRefPubMed
  35. ↵
    McMurray, R. W.. 1996. Adhesion molecules in autoimmune disease. Semin. Arthritis Rheum. 25: 215-233.
    OpenUrlCrossRefPubMed
  36. ↵
    Yu, Q., I. Stamenkovic. 2000. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev. 14: 163-176.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Schonbeck, U., F. Mach, P. Libby. 1998. Generation of biologically active IL-1β by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1β processing. J. Immunol. 161: 3340-3346.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    McQuibban, G. A., J. H. Gong, E. M. Tam, C. A. McCulloch, I. Clark-Lewis, C. M. Overall. 2000. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289: 1202-1206.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Itoh, T., H. Matsuda, M. Tanioka, K. Kuwabara, S. Itohara, R. Suzuki. 2002. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J. Immunol. 169: 2643-2647.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Lauffenburger, D. A., A. F. Horwitz. 1996. Cell migration: a physically integrated molecular process. Cell 84: 359-369.
    OpenUrlCrossRefPubMed
  41. ↵
    Hemler, M. E., M. J. Elices, C. Parker, Y. Takada. 1990. Structure of the integrin VLA-4 and its cell-cell and cell-matrix adhesion functions. Immunol. Rev. 114: 45-65.
    OpenUrlCrossRefPubMed
  42. ↵
    Jackson, D. Y.. 2002. α4 integrin antagonists. Curr. Pharm. Des. 8: 1229-1253.
    OpenUrlCrossRefPubMed
  43. ↵
    Davenport, R. J., J. R. Munday. 2007. α4-integrin antagonism–an effective approach for the treatment of inflammatory diseases?. Drug Discov. Today 12: 569-576.
    OpenUrlCrossRefPubMed
  44. ↵
    Palmer, E. L., C. Ruegg, R. Ferrando, R. Pytela, D. Sheppard. 1993. Sequence and tissue distribution of the integrin α9 subunit, a novel partner of β1 that is widely distributed in epithelia and muscle. J. Cell Biol. 123: 1289-1297.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    Smith, L. L., H. K. Cheung, L. E. Ling, J. Chen, D. Sheppard, R. Pytela, C. M. Giachelli. 1996. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by α9β1 integrin. J. Biol. Chem. 271: 28485-28491.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    Tanaka, D., T. Kagari, H. Doi, T. Shimozato. 2006. Essential role of neutrophils in anti-type II collagen antibody and lipopolysaccharide-induced arthritis. Immunology 119: 195-202.
    OpenUrlCrossRefPubMed
  47. ↵
    Shim, H., S. Oishi, N. Fujii. 2008. Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors. Semin. Cancer Biol. 19: 123-134.
    OpenUrlPubMed
  48. ↵
    Rollins, B. J.. 1997. Chemokines. Blood 90: 909-928.
    OpenUrlFREE Full Text
  49. ↵
    Szekanecz, Z., A. E. Koch. 2008. Vascular involvement in rheumatic diseases: ‘vascular rheumatology.’. Arthritis Res. Ther. 10: 224
    OpenUrlCrossRefPubMed
  50. ↵
    Li, X., L. Qin, M. Bergenstock, L. M. Bevelock, D. V. Novack, N. C. Partridge. 2007. Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts. J. Biol. Chem. 282: 33098-33106.
    OpenUrlAbstract/FREE Full Text
  51. ↵
    Han, J. H., S. J. Choi, N. Kurihara, M. Koide, Y. Oba, G. D. Roodman. 2001. Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κB ligand. Blood 97: 3349-3353.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    Gronthos, S., A. C. Zannettino. 2007. The role of the chemokine CXCL12 in osteoclastogenesis. Trends Endocrinol. Metab. 18: 108-113.
    OpenUrlCrossRefPubMed
  53. ↵
    Salmon, M., D. Scheel-Toellner, A. P. Huissoon, D. Pilling, N. Shamsadeen, H. Hyde, A. D. D'Angeac, P. A. Bacon, P. Emery, A. N. Akbar. 1997. Inhibition of T cell apoptosis in the rheumatoid synovium. J. Clin. Invest. 99: 439-446.
    OpenUrlCrossRefPubMed
  54. ↵
    Bombara, M. P., D. L. Webb, P. Conrad, C. W. Marlor, T. Sarr, G. E. Ranges, T. M. Aune, J. M. Greve, M. L. Blue. 1993. Cell contact between T cells and synovial fibroblasts causes induction of adhesion molecules and cytokines. J. Leukocyte Biol. 54: 399-406.
    OpenUrlAbstract
  55. ↵
    Brennan, F. M., I. B. McInnes. 2008. Evidence that cytokines play a role in rheumatoid arthritis. J. Clin. Invest. 118: 3537-3545.
    OpenUrlCrossRefPubMed
  56. ↵
    Feldmann, M., F. M. Brennan, R. N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14: 397-440.
    OpenUrlCrossRefPubMed
  57. ↵
    Horai, R., S. Saijo, H. Tanioka, S. Nakae, K. Sudo, A. Okahara, T. Ikuse, M. Asano, Y. Iwakura. 2000. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191: 313-320.
    OpenUrlAbstract/FREE Full Text
  58. ↵
    Noda, M., G. A. Rodan. 1989. Type β transforming growth factor regulates expression of genes encoding bone matrix proteins. Connect Tissue Res. 21: 71-75.
    OpenUrlPubMed
  59. ↵
    Heino, J., R. A. Ignotz, M. E. Hemler, C. Crouse, J. Massague. 1989. Regulation of cell adhesion receptors by transforming growth factor-β: concomitant regulation of integrins that share a common β1 subunit. J. Biol. Chem. 264: 380-388.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Immunology: 182 (12)
The Journal of Immunology
Vol. 182, Issue 12
15 Jun 2009
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Advertising (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
α9 Integrin and Its Ligands Constitute Critical Joint Microenvironments for Development of Autoimmune Arthritis
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
α9 Integrin and Its Ligands Constitute Critical Joint Microenvironments for Development of Autoimmune Arthritis
Masashi Kanayama, Daisuke Kurotaki, Junko Morimoto, Tsuyoshi Asano, Yutaka Matsui, Yosuke Nakayama, Yoshinari Saito, Koyu Ito, Chiemi Kimura, Norimasa Iwasaki, Koji Suzuki, Tanenobu Harada, Hong Mei Li, Jun Uehara, Tadaaki Miyazaki, Akio Minami, Shigeyuki Kon, Toshimitsu Uede
The Journal of Immunology June 15, 2009, 182 (12) 8015-8025; DOI: 10.4049/jimmunol.0900725

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
α9 Integrin and Its Ligands Constitute Critical Joint Microenvironments for Development of Autoimmune Arthritis
Masashi Kanayama, Daisuke Kurotaki, Junko Morimoto, Tsuyoshi Asano, Yutaka Matsui, Yosuke Nakayama, Yoshinari Saito, Koyu Ito, Chiemi Kimura, Norimasa Iwasaki, Koji Suzuki, Tanenobu Harada, Hong Mei Li, Jun Uehara, Tadaaki Miyazaki, Akio Minami, Shigeyuki Kon, Toshimitsu Uede
The Journal of Immunology June 15, 2009, 182 (12) 8015-8025; DOI: 10.4049/jimmunol.0900725
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Disclosures
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Anti-inflammatory and anti-bacterial effect of polyacetylene compound from Cirsium japonicum var. ussuriense (54.19)
  • CD11b+/Gr-1int monocytic myeloid derived suppressor cells contribute to high-fat induced inflammation and delayed tolerance in mouse liver (54.15)
  • Antigen presentation by dendritic cells in the aortic wall triggers T helper immune responses in atherosclerosis (54.16)
Show more INFLAMMATION

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606